41st week of 2020 patent applcation highlights part 11 |
Patent application number | Title | Published |
20200316087 | NOVEL COMBINATION THERAPY FOR ANXIETY DISORDERS, EPILEPSY, AND PAIN - Combination therapy with a GABA | 2020-10-08 |
20200316088 | DOSING REGIMEN FOR SEDATION WITH CNS 7056 (REMIMAZOLAM) - The invention relates to a dosing regimen for sedation with the fast-acting benzodiazepine CNS 7056 in combination with an opioid, in particular fentanyl, whereas CNS 7056 is given in Ft dose of 2 to 20 mg, preferably between 4 and 9 mg and most preferably between 5 and 8 mg. | 2020-10-08 |
20200316089 | 1,2-DIHYDRO-3H-PYRAZOL-3-ONE COMPOUNDS AND METHODS OF USING SAME - The present disclosure relates to 1,2-dihydro-3H-pyrazol-3-one compounds and methods of using them to induce self-renewal of stem/progenitor supporting cells, including inducing the stem/progenitor cells to proliferate while maintaining, in the daughter cells, the capacity to differentiate into tissue cells. | 2020-10-08 |
20200316090 | TARGETED THERAPEUTICS - The present invention provides pharmacological compounds including an effector moiety conjugated to a binding moiety that directs the effector moiety to a biological target of interest. Likewise, the present invention provides compositions, kits, and methods (e.g., therapeutic, diagnostic, and imaging) including the compounds. The compounds can be described as a protein interacting binding moiety-drug conjugate (SDC-TRAP) compounds, which include a protein interacting binding moiety and an effector moiety. For example, in certain embodiments directed to treating cancer, the SDC-TRAP can include an Hsp90 inhibitor conjugated to a cytotoxic agent as the effector moiety. | 2020-10-08 |
20200316091 | METHOD FOR PROVIDING CONTRACEPTION - The invention relates to a method for providing contraception in a woman, wherein the woman is subjected to hormonal combined contraceptive but experiments at least one misuse of said hormonal combined contraceptive and wherein the method comprises administering ulipristal acetate or a metabolite thereof within 120 hours after said at least one misuse and resuming the hormonal combined contraceptive within 24 hours after the intake of ulipristal acetate in said woman. | 2020-10-08 |
20200316092 | METHODS OF DIAGNOSIS AND TREATMENT OF LIVER DISEASES USING OBETICHOLIC ACID - The disclosure relates to methods of using obeticholic acid for the treatment of various diseases and conditions. | 2020-10-08 |
20200316093 | ABIRATERONE ACETATE LIPID FORMULATIONS - Abiraterone acetate lipid formulations. | 2020-10-08 |
20200316094 | COMPOSITIONS FOR USE IN STIMULATING BONE GROWTH - The present invention relates to use of a composition for maintenance of bone and/or cartilage health or prevention, alleviation and/or treatment of bone and/or cartilage disorders. | 2020-10-08 |
20200316095 | COMPOSITIONS COMPRISING ACETYLSALICYLIC ACID AND A PHOSPHATE SALT - The present invention relates to a novel two-component system comprising acetylsalicylic acid (ASA) and which is particularly useful in providing an aqueous solution of ASA for immediate peroral administration. | 2020-10-08 |
20200316096 | COMBINATION OF DIET AND DRUG THERAPY FOR TREATING CANCER - The present disclosure provides a unique novel diet-drug combination, and method thereof, for cancer management, with synergistic and non-toxic effects. | 2020-10-08 |
20200316097 | STORAGE-STABLE READY-TO-USE INJECTABLE FORMULATIONS OF FOSAPREPITANT DIMEGLUMINE - The present application provides a stable, ready-to-use fosaprepitant dimeglumine formulation which is easy to administer without need of any reconstitution step and has a desirable solubility, stability and safety profile. The concentration of the fosaprepitant dimeglumine in the liquid formulation is preferably less than about 80 mg/ml, or more preferably between about 20 mg/ml to about 60 mg/ml. In certain embodiments, the liquid formulation retains at least about 90% chemical stability of the fosaprepitant dimeglumine after storage for a commercially reasonable amount of time at a temperature between about 0° C. to about 40° C. | 2020-10-08 |
20200316098 | TERNARY MIXTURES OF 6'-SL, LNnT and LST c - A mixture of human milk oligosaccharides that consists essentially of 6′-SL, LNnT and LSTc, made by treating 6′-SL and LNnT in the presence of an α2,6-transsialidase. | 2020-10-08 |
20200316099 | ISOTOPOLOGUES OF 5-AZACYTIDINE - The present disclosure provides pharmaceutical compositions comprising cytidine analogs for oral administration, wherein the compositions release the cytidine analog substantially in the stomach. Also provided are methods of treating diseases and disorders using the oral formulations provided herein. | 2020-10-08 |
20200316100 | HALOALKYL FUCOSE-CONTAINING SELECTIN ANTAGONISTS - Compounds, compositions, and methods for treatment and/or prevention of at least one disease, disorder, and/or condition by inhibiting binding of an E-selectin to an E-selectin ligand are disclosed. For example, haloalkyl fucose-containing E-selectin antagonists and compositions comprising at least one such agent are described. | 2020-10-08 |
20200316101 | APPLICATIONS OF TRIACETYL-3-HYDROXYL PHENYL ADENOSINE IN TREATING VASCULAR INFLAMMATIONS OR IMPROVING VASCULAR ENDOTHELIUM FUNCTIONS - Applications of 2′,3′,5′-tri-O-acetyl-N | 2020-10-08 |
20200316102 | METHODS AND PHARMACEUTICAL COMPOSITION FOR THE TREATMENT OF NEURODEGENERATIVE DISEASE - In the present invention it is shown that the inactivation of the Pyk2 gene does not alter hippocampal development but prevents hippocampal-dependent memory tasks and LTP. Inventors clearly provide evidence for multiple roles of Pyk2 in spine morphology and postsynaptic structure. Thus, the inventors used direct overexpression of PYK2 by AAV-mediated gene transfer into the brain of Huntington's and Alzheimer's mouse models and found that overexpression of PYK2 in these 2 models improves synaptic properties and spine density deficits which is also accompanied by a rescue of spatial memory. Accordingly it was demonstrated that PYK2 may restore cognitive functions in neurodegenerative diseases. Thus the present invention relates to methods and pharmaceutical compositions for the treatment of neurodegenerative disease. In particular the present invention relates to a method of treating neurodegenerative disease in a subject in need thereof comprising administering to the subject a therapeutically effective amount of a vector which comprises a nucleic acid molecule encoding for PYK2 polypeptide. | 2020-10-08 |
20200316103 | MEDICINAL COMPOSITION - A medicinal composition for preventing, ameliorating, or at least reducing the pain intensity associated with a headache is disclosed. The composition comprises a therapeutic amount of a plurality of Humulus lupulus, Tanacetum parthenium, and Vitamin B12. | 2020-10-08 |
20200316104 | MicroRNA-based methods and assays for osteocarcinoma - Provided are methods and compositions useful in the diagnosis, treatment, and monitoring of osteosarcoma. Antisense to certain microRNA (miRNA) found to be associated with cancer stem cells (CSCs) or tumor-initiating cells (TICs) of osteosarcoma are useful to suppress tumor growth and metastasis, and prolong survival. Antisense oligonucleotides to miR-133a are synergistic in combination with standard chemotherapy such as cisplatin in the treatment of osteosarcoma. | 2020-10-08 |
20200316105 | MicroRNA-Based Methods and Assays for Osteocarcinoma - Provided are methods and compositions useful in the diagnosis, treatment, and monitoring of osteosarcoma. Antisense to certain microRNA (miRNA) found to be associated with cancer stem cells (CSCs) or tumor-initiating cells (TICs) of osteosarcoma are useful to suppress tumor growth and metastasis, and prolong survival. Antisense oligonucleotides to miR-133a are synergistic in combination with standard chemotherapy such as cisplatin in the treatment of osteosarcoma. | 2020-10-08 |
20200316106 | AQUEOUS COMPOSITION FOR LIVESTOCK ANIMALS - Aqueous compositions and methods using the compositions for preventing or minimizing live body weight loss in livestock animals subjected to a prolonged period of feed deprivation, e.g., such as during the period before slaughter or during a period surrounding transportation from one location to another location (e.g., before, during and/or after), and/or for minimizing carcass weight loss or carcass yield loss, and/or meat quality deterioration and/or for preventing or minimizing deterioration of the well-being or health of livestock animals subjected to a prolonged period of feed deprivation, e.g., such as during the period before slaughter or during a period surrounding transportation from one location to another location (e.g., before, during and/or after). | 2020-10-08 |
20200316107 | PHARMACEUTICAL COMPOSITION FOR SUPPRESSING SPINAL CORD ISCHEMIA DISORDER - To provide a gaseous pharmaceutical composition for suppressing spinal cord ischemic disorder, comprising carbon dioxide. | 2020-10-08 |
20200316108 | Methods and Compositions for Treating Chlorine-Gas Induced Lung Injury - The invention provides methods and compositions for treating and/or preventing chlorine-gas induced lung injury with sodium thiosulfate. | 2020-10-08 |
20200316109 | TREATMENT AND PREVENTION OF THE COMMON COLD USING POVIDONE-IODINE - The present invention provides a method of treating and preventing the common cold and associated secondary illnesses in a human subject, when the common cold is caused by viruses. The method comprises applying to the nasal passages of the human subject at ambient temperature, an effective amount of a pharmaceutical preparation comprising povidone-iodine (PVP-I) at a concentration of greater than 0.10% w/v and less than 2.5% in which at least 50% of the PVP-I is not associated with liposomes or other particulate carriers. | 2020-10-08 |
20200316110 | METHOD FOR BONE TISSUE REGENERATION IN EXPERIMENTS - The invention relates to the treatment of different bone injuries, particularly fractures and fissure fractures. In order to reduce the time taken for bone tissue to regenerate at the site of damage, a method is used for regenerating bone tissue by fixing fragments of the damaged bone with a plaster cast or a bandage made of a polymer material and introducing into the fracture zone an aqueous solution containing 1-hydroxyethylidene diphosphonic acid in an amount of (1.80-2.06) g/l, anhydrous calcium chloride in an amount of (1.44-2.22) g/l, gadolinium (III) nitrate hexahydrate in an amount of (0.30-0.40) g/l and dysprosium (III) chloride hexahydrate in an amount of (0.038-0.076) g/l, with a pH of (7.3-7.8), wherein, prior to being introduced into the fracture zone, the above solution is brought to a temperature of (30-100)° C., is held at this temperature for (1-48) hours and is then cooled to room temperature. | 2020-10-08 |
20200316111 | PHARMACEUTICAL COMPOSITIONS - Pharmaceutical compositions for oral administration, in particular administration as an oral delivery system to be swallowed directly or capable of disintegration in the oral cavity, comprising iron oxy-hydroxide in high loading. | 2020-10-08 |
20200316112 | PHARMACEUTICAL COMPOSITIONS - Pharmaceutical compositions for oral administration, in particular administration as an oral delivery system to be swallowed directly or capable of disintegration in the oral cavity, comprising iron oxy-hydroxide in high loading. | 2020-10-08 |
20200316113 | USE OF COMPOSITION COMPRISING FERROUS AMINO ACID CHELATE IN MANUFACTURE OF MEDICAMENT FOR INHIBITING ANGIOGENESIS - The present invention is related to a use of a composition comprising ferrous amino acid chelate for the manufacture of a medicament for inhibiting angiogenesis, wherein the medicament comprises an effective amount of the ferrous amino acid chelate composition and a pharmaceutically acceptable carrier. The amino acid can be glycine and the angiogenesis can be related to cancer or eye disease. | 2020-10-08 |
20200316114 | HAIR RESTORER PREPARATION OR FOOD SUPPLEMENT - The invention relates to a hair restorer preparation or food supplement ( | 2020-10-08 |
20200316115 | METHODS AND COMPOSITIONS FOR MITOCHONDRIAL REPLACEMENT THERAPY - The invention features methods, kits, and compositions for mitochondrial replacement in the treatment of disorders arising from mitochondrial dysfunction. The invention also features methods of diagnosing neuropsychiatric (e.g., bipolar disorder) and neurodegenerative disorders based on mitochondrial structural abnormalities. | 2020-10-08 |
20200316116 | METHOD FOR THE TREATMENT OF BETA-THALASSEMIA - Described herein are methods and compositions for treating a beta-thalassemia. p | 2020-10-08 |
20200316117 | METHOD FOR PRODUCING MYELOID-DERIVED SUPPRESSOR CELLS, MYELOID-DERIVED SUPPRESSOR CELLS PRODUCED THEREBY, AND METHODS THEREOF - The present invention relates to a method for inducing differentiation of bone marrow cells into myeloid-derived suppressor cells (MDSCs) by treating the bone marrow cells with a toll-like receptor agonist (TLR agonist) or type I interferon, or for inducing dendritic cells from the MDSCs. | 2020-10-08 |
20200316118 | TETHERED INTERLEUKIN-2 TO ITS RECEPTOR IL-2RBETA, A PLATFORM TO ENHANCE NATURAL KILLER AND REGULATORY T CELL ACTIVITY - Fusion proteins comprising IL2 and IL2Rβ (e.g., CIRB), IL2, IL2Rβ and IL21R (e.g., CIRB21), and/or comprising IL2, IL2Rβ, and CD28 (e.g., CIRB28); natural killer (NK) cells that express the fusion proteins and methods of use thereof, e.g., to treat subjects with cancer; and regulatory T cells (T-regs) that express a fusion protein comprising IL2, IL2Rβ, and CD28 and methods of use thereof, e.g., to treat subjects with autoimmune disease or GVHD. | 2020-10-08 |
20200316119 | CMV EPITOPES - Provided herein are compositions and methods related to the treatment of a CMV infection and/or cancer in a subject. | 2020-10-08 |
20200316120 | METHODS FOR IDENTIFYING ACTIVATING ANTIGEN RECEPTOR (aCAR)/INHIBITORY CHIMERIC ANTIGEN RECEPTOR (iCAR) PAIRS FOR USE IN CANCER THERAPIES - The present invention provides a method for identifying a target pair comprising i) an inhibitory chimeric antigen receptor (iCAR) or a protective chimeric antigen receptor (pCAR) capable of preventing or attenuating undesired activation of an effector immune cell, wherein the iCAR or pCAR target is directed to a target extracellular polymorphic epitope, and ii) an activating chimeric antigen receptor (aCAR), wherein the aCAR is directed to a target non-polymorphic cell surface epitope of a protein, as well as methods of making and use of such pairs in the treatment of cancer. | 2020-10-08 |
20200316121 | METHODS OF ISOLATING T CELLS HAVING ANTIGENIC SPECIFICITY FOR A P53 CANCER-SPECIFIC MUTATION - Disclosed are methods of isolating T cells having antigenic specificity for a mutated p53 amino acid sequence encoded by a cancer-specific p53 mutation, the method comprising: inducing autologous APCs of the patient to present the mutated p53 amino acid sequence; co-culturing autologous T cells of the patient with the autologous APCs that present the mutated p53 amino acid sequence; and selecting the autologous T cells. Also disclosed are related methods of preparing a population of cells, populations of cells, pharmaceutical compositions, and methods of treating or preventing cancer. | 2020-10-08 |
20200316122 | METHODS OF PRODUCING T CELL POPULATIONS USING P38 MAPK INHIBITORS - Provided are methods of producing an isolated population of T cells for adoptive cell therapy, the method comprising culturing isolated T cells in vitro in the presence of a p38 mitogen activated protein kinase (p38 MAPK) inhibitor, wherein the T cells have antigenic specificity for a cancer antigen. Also provided are related isolated populations of T cells, pharmaceutical compositions, and methods of treating or preventing cancer in a mammal. | 2020-10-08 |
20200316123 | Cancer Immunotherapy - Methods of providing populations of NKT and/or γδ T cells, and their use, e.g., in therapies such as cancer immunotherapy. | 2020-10-08 |
20200316124 | NOVEL GAMMA DELTA T-CELL RECEPTOR AND ITS LIGAND - The present disclosure relates to a new T-cell receptor (TCR), in particular at least one complementarity-determining region (CDR) thereof; a T-cell expressing said TCR; a clone expressing said TCR; a vector encoding said TCR; a soluble version of said TCR; a pharmaceutical composition or immunogenic agent or bispecific or vaccine comprising said TCR, said cell, said clone or said vector; said TCR or said cell or said clone or said vector or said pharmaceutical composition or immunogenic agent or bispecific or vaccine for use in the treatment of cancer; a method of treating cancer using said TCR, said cell, said clone, said vector, said pharmaceutical composition, immunogenic agent, bispecific or vaccine comprising said TCR; and a ligand with which said TCR binds. | 2020-10-08 |
20200316125 | NOVEL PEPTIDES AND COMBINATION OF PEPTIDES FOR USE IN IMMUNOTHERAPY AGAINST EPITHELIAL OVARIAN CANCER AND OTHER CANCERS - The present invention relates to peptides, proteins, nucleic acids and cells for use in immunotherapeutic methods. In particular, the present invention relates to the immunotherapy of cancer. The present invention furthermore relates to tumor-associated T-cell peptide epitopes, alone or in combination with other tumor-associated peptides that can for example serve as active pharmaceutical ingredients of vaccine compositions that stimulate anti-tumor immune responses, or to stimulate T cells ex vivo and transfer into patients. Peptides bound to molecules of the major histocompatibility complex (MHC), or peptides as such, can also be targets of antibodies, soluble T-cell receptors, and other binding molecules. | 2020-10-08 |
20200316126 | NOVEL PEPTIDES AND COMBINATION OF PEPTIDES FOR USE IN IMMUNOTHERAPY AGAINST EPITHELIAL OVARIAN CANCER AND OTHER CANCERS - The present invention relates to peptides, proteins, nucleic acids and cells for use in immunotherapeutic methods. In particular, the present invention relates to the immunotherapy of cancer. The present invention furthermore relates to tumor-associated T-cell peptide epitopes, alone or in combination with other tumor-associated peptides that can for example serve as active pharmaceutical ingredients of vaccine compositions that stimulate anti-tumor immune responses, or to stimulate T cells ex vivo and transfer into patients. Peptides bound to molecules of the major histocompatibility complex (MHC), or peptides as such, can also be targets of antibodies, soluble T-cell receptors, and other binding molecules. | 2020-10-08 |
20200316127 | NOVEL PEPTIDES AND COMBINATION OF PEPTIDES FOR USE IN IMMUNOTHERAPY AGAINST EPITHELIAL OVARIAN CANCER AND OTHER CANCERS - The present invention relates to peptides, proteins, nucleic acids and cells for use in immunotherapeutic methods. In particular, the present invention relates to the immunotherapy of cancer. The present invention furthermore relates to tumor-associated T-cell peptide epitopes, alone or in combination with other tumor-associated peptides that can for example serve as active pharmaceutical ingredients of vaccine compositions that stimulate anti-tumor immune responses, or to stimulate T cells ex vivo and transfer into patients. Peptides bound to molecules of the major histocompatibility complex (MHC), or peptides as such, can also be targets of antibodies, soluble T-cell receptors, and other binding molecules. | 2020-10-08 |
20200316128 | UNIVERSAL REPORTER CELL ASSAY FOR SPECIFICITY TEST OF NOVEL ANTIGEN BINDING MOIETIES - The present invention generally relates to specificity assays using cell cultures, in particular to chimeric antigen receptor (CAR) expressing reporter T (CAR-T) cell assays to test novel antigen binding moieties in different formats. Furthermore, the present invention relates to the use of CAR-T cells, transfected/transduced with an engineered chimeric antigen receptor (CAR) comprising a target antigen binding moiety capable of specific binding to a recognition domain of an antigen binding molecule. The invention also relates to methods and kits for specificity testing of a candidate antigen binding moiety and/or nucleic acid molecules and vectors expressing engineered CARs. | 2020-10-08 |
20200316129 | ENGINEERED ANUCLEATE CELLULAR AND EXTRACELLULAR VESICLES AS A NOVEL BIOLOGICS DELIVERY PLATFORM - The present invention is based on the discovery of genetic engineered induced pluripotent stem cells (iPSCs) that produce one or more therapeutic entities such as antibodies and nucleic acids that when administered to a subject, will treat or prevent disease. The present invention also combines EMV technology with iPSC technology creating a powerful new drug delivery platform. | 2020-10-08 |
20200316130 | MATERIALS AND METHODS FOR ENHANCING BONE CELL DIFFERENTIATION - This document provides materials and methods for enhancing bone cell differentiation. For example, compositions containing an epigenetic drug, an actin modulator, and/or one or more osteogenic differentiation factors that can be used to enhance bone cell differentiation are provided. | 2020-10-08 |
20200316131 | PHARMACEUTICAL COMPOSITION FOR TREATING DRUG-RESISTANT CANCER COMPRISING EXOSOMES DERIVED FROM DIFFERENTIATING STEM CELLS AS AN ACTIVE INGREDIENT - The present invention relates to a method of treating a subject having drug-resistant cancer, comprising administering a composition comprising exosomes derived from differentiating stem cells as an active ingredient. The exosomes isolated differentiating stem cells according to the present invention have an excellent expression rate of bioactive factors affecting differentiation and have an effect of facilitating reprogramming of cancer stem cells and differentiating them into cancer cells with weakened drug resistance. | 2020-10-08 |
20200316132 | COMPOSITIONS AND METHODS FOR WILLIAMS SYNDROME (WS) THERAPY - The present disclosure relates to compositions and methods for treating Williams syndrome (WS), herein identified as a neurodevelopmental oligodendrocyte hypomyelination-associated disease, and to compositions and methods for treatment of other neurodevelopmental myelination abnormality diseases or disorders. | 2020-10-08 |
20200316133 | FAT AND MEDICAL USES THEREOF - The present invention refers to micro-fragmented fat or a composition comprising micro-fragmented fat for use in the treatment of a systemic disease, preferably associated to or caused by sepsis. Moreover, the micro-fragmented fat or the composition comprising micro-fragmented fat is used for treating a systemic, inflammatory, immune, or chronic disease, said disease being intended as a consequence of septic disease. Preferably, the micro-fragmented fat is useful for treating both the acute (early) and late stages of sepsis. | 2020-10-08 |
20200316134 | Biological Scaffold Comprising Therapeutic Cells - Methods of implanting therapeutic cells in a subject and methods of preparing pancreatic islet cells for implantation into a subject, prior to implantation into a subject, are provided herein. | 2020-10-08 |
20200316135 | METHODS OF PRODUCING PANCREATIC HORMONES - Disclosed herein are methods of producing pancreatic hormone-expressing cells by first differentiating pluripotent cells in cell culture so as to produce endodermal cells, the endodermal cells being competent to further differentiate into hormone-expressing cells capable of secreting at least one pancreatic hormone in response to a physiological signal, and then, transplanting the cultured endodermal cells into an organism, such as an organism in need of an endocrine cell therapy. | 2020-10-08 |
20200316136 | NON-WINTERIZED, STANDARDIZED MARINE SOURCE OIL PRODUCTS AND METHODS OF MAKING THEREOF - Disclosed is a liquid medicament/supplement composition including a non-winterized marine source oil (e.g., oil derived from fish, krill, and/or squid), a food grade or pharmaceutically acceptable form of vitamin D | 2020-10-08 |
20200316137 | METHOD FOR PROCESSING TRADITIONAL CHINESE MEDICINE USING CALCIUM-BASED ION SOLUTION AND APPLICATION THEREOF - A method for processing traditional Chinese medicine using a calcium-based ion solution and an application thereof. A solution formed by a calcium-based ion solution and Chinese spirits is used to soak a traditional Chinese medicine prescription; the calcium-based ion solution refers to a solution containing calcium ions with a mass percentage of 0.3-10%; and the Chinese spirits is a spirit containing more than 35% alcohol by volume. Also provided is an application of a soaking liquid for processing traditional Chinese medicine in preparing, from a traditional Chinese medicine prescription, a meridians and collaterals administration agent applied on skin, a preparation extracted from traditional Chinese medicine soaked using a soaking solution formed by “a calcium-based ion solution and a spirit” has a better effect of guiding skin penetration. | 2020-10-08 |
20200316138 | FAECALIBACTERIUM PRAUSNITZII STRAINS FOR TREATING AND PREVENTING GASTROINTESTINAL PAIN - The present invention relates to a bacterial strain of the | 2020-10-08 |
20200316139 | STABLE PROBIOTIC COMPOSITION FOR THE MANAGEMENT OF LACTOSE INTOLERANCE - The present invention discloses a stable probiotic composition comprising | 2020-10-08 |
20200316140 | METHOD AND COMPOSITION FOR THERAPEUTIC MANAGEMENT OF GLUTEN INTOLERANCE - The present invention discloses the potential of probiotic bacteria | 2020-10-08 |
20200316141 | Composition To Support Healthy Brain Function - Described herein is a composition containing probiotic bacteria and a fermentate that can increase IPA production. The composition comprises one or more bacteria having a nucleic acid sequence with at least 80% homology to the nucleic acid sequence of SEQ ID NO: 1, a fermentate comprising soy flour, a yeast, and a proteolytic enzyme, and an excipient, carrier, and/or diluent. The composition can promote brain health and/or nervous system function. | 2020-10-08 |
20200316142 | PAIRING PROBIOTICS AND PREBIOTICS, METHODS FOR GROWTH AND USE, SEPARATELY AND IN COMBINATION - A method for growing probiotic organisms wherein the growth media includes prebiotics especially selected and prepared to be paired with the probiotic organisms being grown. The prebiotic formula is optimized to grow the desired probiotic organisms, as well as important byproducts of the growth process. Specialized freeze-drying buffers may also be paired with certain probiotic organisms for the freeze-drying process. Specific products may utilize selected probiotic organisms grown and supported with paired prebiotic formulas to promote and maintain physiological health in a subject. | 2020-10-08 |
20200316143 | COMPOSITIONS AND METHODS FOR MANAGEMENT OF ATROPHIC GASTRITIS AND COLITIS - The present invention discloses a method for therapeutic management of atrophic gastritis and colitis using a composition comprising | 2020-10-08 |
20200316144 | BIFIDOBACTERIA FOR TREATING DIABETES AND RELATED CONDITIONS - This invention relates to new uses of | 2020-10-08 |
20200316145 | PROBIOTICS FOR USE IN REDUCING THE INCIDENCE AND DURATION OF ILLNESS - The present invention provides probiotic compositions suitable for reducing the incidence and duration of human illness. In particular, the present invention provides methods and compositions suitable for preventing disease in young children. In some particularly preferred embodiments, the present invention finds use in the prevention respiratory disease in children. | 2020-10-08 |
20200316146 | SYNTHETICALLY ENVELOPED VIRUS - A method of modifying a virus for in vivo delivery to a region of interest includes forming an enveloping composition including a lipid conjugate formed by conjugating at least one lipid with at least one hydrophilic compound via a linkage which is cleavable under conditions present in the region of interest and combining the virus with the enveloping composition to encompass the virus within the enveloping structure. | 2020-10-08 |
20200316147 | COMPOSITIONS AND METHODS RELATED TO xCT PEPTIDES - Certain embodiments are directed to composition for inducing an immune response against xCT that is directed to cancer stem cells expressing xCT. | 2020-10-08 |
20200316148 | METHOD OF SYNTHESIZING CUSTARD APPLE PEEL NANOPARTICLES - The custard apple peel nanoparticles may be manufactured by extracting custard apple peels in a solvent, spraying the custard apple peel extracts into boiling water under ultrasonic conditions to produce a first mixture, sonicating the mixture, stirring the mixture, and drying the mixture to obtain custard apple peel nanoparticles. In an embodiment, the custard apple peel may be peel of | 2020-10-08 |
20200316149 | METHOD OF SYNTHESIZING CUSTARD APPLE PEEL NANOPARTICLES - The custard apple peel nanoparticles may be manufactured by extracting custard apple peels in a solvent, spraying the custard apple peel extracts into boiling water under ultrasonic conditions to produce a first mixture, sonicating the mixture, stirring the mixture, and drying the mixture to obtain custard apple peel nanoparticles. In an embodiment, the custard apple peel may be peel of | 2020-10-08 |
20200316150 | GASTRORETENTIVE SUSTAINED RELEASE FORMULATIONS OF BERGENIA CILIATA - The present invention is related to a novel gastroretentive swellable oral dosage form for sustained or delayed release of bergenin, a active constituent of | 2020-10-08 |
20200316151 | CANNABINOID, MENTHOL AND CAFFEINE DISSOLVABLE FILM COMPOSITIONS, DEVICES AND METHODS - The present disclosure relates to a dissolvable thin oral tape, film or strip or segment thereof composition or device, including a film former, at least one cannabinoid, menthol, caffeine and vitamins, where the menthol component can be a stabilized menthol composition comprising menthol and at least one menthol stabilizer compound including undecylenic acid methyl ester, undecylenic acid or a salt of undecylenic acid. | 2020-10-08 |
20200316152 | METHODS FOR TREATING NEUROLOGIAL DISORDERS USING NUTRIENT COMPOSITIONS - Nutrient compositions comprising botanical extracts and methods of their use for treating, inter alia, autism or apraxia and/or ameliorating one or more symptoms thereof are disclosed. The use of such compositions for enhancing cognitive function and/or one or more aspects thereof, or for treating stroke or seizures and/or ameliorating one or more symptoms thereof are also disclosed. | 2020-10-08 |
20200316153 | EXTERNALLY-USED TRADITIONAL CHINESE MEDICINE PREPARATION FOR TREATING RHINITIS, AND PREPARATION METHOD THEREFOR - An externally-used traditional Chinese medicine preparation for treating rhinitis, and a preparation method therefor. The externally-used traditional Chinese medicine preparation is prepared by using the following components in parts by weight: 1 to 6 parts of herba asari, 8 to 12 parts of magnolia flowers, 6 to 20 parts of cocklebur fruits, 3 to 8 parts of small centipeda herb, 1 to 6 parts of cutch, 15 to 20 parts of roots of podophyllum hexandrum and 7 to 15 parts of borneol. | 2020-10-08 |
20200316154 | METHOD OF MANUFACTURING A BOTANICAL BLEND INCLUDING CANNABINOIDS AND PRODUCT THEREOF - A cannabinoid composition comprising, purified water, hemp extract having a between 30-70% cannabidiol concentration. The hemp extract being a whole plant extract derived hemp. The composition includes 200-800 mg of ajo sacha paste dissolved in the water in a final concentration of 600 mg paste per 60 ml (2 oz) finished product. The composition further includes sangre de grado is added in the standardized aqueous commercial form at a concentration of 0.5 ml per 60 ml of finished product. The composition includes an excipient chosen from the group consisting of emulsifiers, preservatives, fragrance, flavorings, a carrier oil, and combinations thereof. A method of the invention includes adding these components together to form the composition. In particular, the method includes dissolving equal amounts of 30× Ajo Sacha paste in equal weight hot purified water. Providing a botanical carrier oil and mixing hep CBD oil, commercial Sangre de Grado solution, and Ajo Sacha solution to the botanical carrier oil. | 2020-10-08 |
20200316155 | BENIGN PROSTATIC HYPERPLASIA ADD-ON THERAPY - The present invention is directed to therapeutic methods for treating benign prostatic hyperplasia (BPH) in a subject comprising administering an effective amount of a herbal mixture, and an anti-BPH agent to said subject where said herbal mixture comprises | 2020-10-08 |
20200316156 | NASAL BALM FOR RELIEVING ALLERGIC RHINITIS SYMPTOMS - A nasal balm including, by weight, 10-50% of shea butter; 10-50% of coconut oil; 10-50% of | 2020-10-08 |
20200316157 | METHOD OF PROCESSING PLANT MATERIAL - The present invention relates to a method of processing plant material to provide products such as food products, dietary supplements, pharmaceuticals, cosmetics and fertilizers. In particular, the invention relates to the processing of fruit and vegetable material to provide a product that can be used as a food source, dietary supplement or a pharmaceutical. Even more particularly, the invention relates to processing of green bananas such that the flesh and skin can be processed through separate streams. | 2020-10-08 |
20200316158 | COLLAGEN 7 COMPOSITIONS AND METHODS OF USING THE SAME - The present disclosure relates to compositions comprising collagen 7 and methods of using the same to treat DEB. | 2020-10-08 |
20200316160 | METHODS FOR THE REGULATION OF MATRIX METALLOPROTEINASE EXPRESSION - The disclosure provides methods of reducing MMP-9 expression and/or MMP-9 activity in a mammalian subject. The disclosure also provides methods of increasing TIMP-1 expression and/or TIMP-1 activity in a mammalian subject. The methods comprise administering a therapeutically effective amount of an aromatic-cationic peptide to a subject in need thereof. | 2020-10-08 |
20200316161 | PREVENTIVE AND/OR THERAPEUTIC AGENT FOR OSTEOGENESIS IMPERFECTA AND OTHER DISEASES - Provided is an agent for preventing and/or treating osteogenesis imperfecta, osteoporosis and/or osteoarthritis, the agent comprising a peptide consisting of one of the following amino acid sequences: (a) Val-Asn-Pro-Glu-Ser-Glu-Glu-Glu (SEQ ID NO: 1) and (b) Val-Asn-Pro-Glu (SEQ ID NO: 2). The agent of the present invention can be orally ingested, has osteogenic function, and has a preventive and/or healing-promoting effect on bone fractures and is therefore very useful for prevention and/or treatment of osteogenesis imperfecta, osteoporosis and/or osteoarthritis. | 2020-10-08 |
20200316162 | OXYTOCIN COMPOSITIONS AND METHODS OF USE - Disclosed are oxytocin compositions having a therapeutically effective amount of oxytocin, an analog or derivative of oxytocin, or an oxytocin receptor agonist for the treatment of neonatal abstinence syndrome (“NAS”) in a subject. Also disclosed are methods for the treatment of NAS by administering a therapeutically effective amount of oxytocin, an analog or derivative of oxytocin, or an oxytocin receptor agonist to a subject. | 2020-10-08 |
20200316163 | DOSING REGIMENS AND RELATED COMPOSITIONS AND METHODS - In some aspects, the present invention provides cell-reactive compstatin analogs and compositions comprising cell-reactive compstatin analogs. In some aspects, the invention further provides methods of using cell-reactive compstatin analogs, e.g., treat a complement-mediated disorder, e.g., to inhibit complement-mediated damage to a cell, tissue, or organ. In some aspects, the invention provides long-acting compstatin analogs and compositions comprising long-acting compstatin analogs. In some aspects, the invention further provides methods of using long-acting compstatin analogs, e.g., to treat a complement-mediated disorder, e.g., to inhibit complement-mediated damage to a cell, tissue, or organ. In some aspects, the invention provides targeted compstatin analogs and compositions comprising targeted compstatin analogs. In some aspects, the invention further provides methods of using targeted compstatin analogs, e.g., to treat a complement-mediated disorder, e.g., to inhibit complement-mediated damage to a cell, tissue, or organ. | 2020-10-08 |
20200316164 | FORMULATIONS AND METHODS FOR TREATING ULCERATIVE COLITIS - This invention provides composition and methods to prevent, treat or alleviate a symptom of ulcerative colitis comprising administering to a patient dolcanatide. | 2020-10-08 |
20200316165 | METHOD FOR TREATING OCULAR DISEASES - The present invention provides a method for treating an ocular disease such as age-related macular degeneration (AMD), diabetic retinopathy (DR) or macular edema (ME), which comprises administering to a subject in need thereof a composition comprising a therapeutically effective amount of beauvericin. | 2020-10-08 |
20200316166 | Drug and Method for Treating Liver Diseases Related to Hepatitis B Viruses in Full-Dose Condition - This disclosure relates to medicaments and methods for treating and preventing hepatitis B virus-related liver diseases using sufficient dosage. Specifically, the disclosure provides a method for treating and preventing hepatitis B virus-related liver diseases comprising administering to a subject in need of treatment and prevention a sufficient dosage of a polypeptide or a pharmaceutical composition comprising the polypeptide per day, wherein the polypeptide comprises an amino acid sequence derived from hepatitis B virus (HBV) Pre-S1; the sufficient dosage is a daily dosage at which the polypeptide reaches the saturating level in a liver target organ after the polypeptide is administered in the sufficient dose for several days. | 2020-10-08 |
20200316167 | Screening method for the identification of agents capable of activating CD4+CD25+ regulatory T-cells through interactions with the HIV-1 GP120 binding site on CD4 - The present invention relates specific activation of a regulatory T cell via a specific CD4 epitope and uses thereof, e.g. for the treatment of an autoimmune disease or an allergy or asthma or graft rejection or tolerance induction. | 2020-10-08 |
20200316168 | INHIBITORS OF IGFBP3 BINDING TO TMEM219 FOR TREATMENT OF INTESTINAL DISEASES - The present invention relates to an inhibitor of IGFBP3 binding to TMEM219 and uses thereof for the treatment and/or prevention of an intestinal disease in a subject, in particular the treatment and/or prevention of diabetic enteropathy or inflammatory bowel disease. | 2020-10-08 |
20200316169 | System and Method for the Production, Formulation and Use of Conditioned Media, Cultured Cells and the Factors Included Therein - A technology regarding the production, formulation and use of conditioned media and the factors included therein is disclosed. The conditioned media may be inoculated with animal cells, plant cells and any combination thereof. The inoculations may occur simultaneous or at different times. Cells retrieved from different areas of the animal and/or the plant may also be cultured together to form conditioned media and associated growth factors. | 2020-10-08 |
20200316170 | COMPOSITIONS AND METHODS FOR THE TREATMENT OF MALNUTRITION - The present invention relates to novel liquid or semi-liquid nutritional compositions, and powders to generate such liquid or semi-liquid nutritional compositions, that are beneficial in the treatment of malnutrition and malnutrition-related disorders such as weight loss and muscle wasting. When administered regularly, the nutritional compositions according to the present invention contribute to the reversal of malnutrition and malnutrition-related disorders such as weight loss and/or muscle atrophy. | 2020-10-08 |
20200316171 | METHODS AND COMPOSITIONS FOR TREATMENT OF GAUCHER DISEASE VIA MODULATION OF C5A RECEPTOR - Disclosed are compositions and methods for the reduction of C5a mediated immune inflammation. The methods, in various aspects, may include the step of administering a C5aR antagonist to a subject in need of such treatment. In one aspect, the subject in need may have a lysosomal acid storage disease. Therapeutic kits and articles of manufacture are also disclosed. | 2020-10-08 |
20200316172 | MATURATION OF MUCOSAL DEFENSE AND GUT/LUNG FUNCTION IN THE PRETERM INFANT - The present invention relates to methods for maturing the mucosal defense and rebalancing the immune system preventing a cytokine storm; treatment or prevention of neonatal sepsis, necrotizing enterocolitis, acute and prolonged diarrhea, short bowel syndrome, respiratory illness, respiratory infection, respiratory failure, impaired neurodevelopment and extra uterine growth restriction, the method comprising oral and/or intrapulmonary and/or subcutaneous administration of at least one antimicrobial peptide selected from the group consisting of α-defensins, β-defensins, cathelicidins, lactoferrins/lactoferricins and lysozymes and/or GLP-2 or GLP-2 analogs in a preterm infant or a mother about to give birth to a preterm infant. | 2020-10-08 |
20200316173 | Method of treating cancer with an immune checkpoint inhibitor in combination with another therapeutic agent - A method is provided for treating a cancer patient non-responsive to treatment with a immune checkpoint inhibitor (ICI) by treating the patient with said ICI in combination with an agent that blocks the activity of a dominant factor selected among the plurality of host-driven resistance factors generated in response to treatment of the cancer patient with the ICI, these factors having a fold-change predictive of a non-favorable response of the cancer patient to the treatment with the ICI. | 2020-10-08 |
20200316174 | FRACTURE TARGETED BONE REGENERATION THROUGH PARATHYROID HORMONE RECEPTOR STIMULATION - Disclosed herein includes a drug delivery system comprising at least one peptide and a targeting ligand for bone fracture and/or for bone healing. Some embodiments include a peptide delivery system comprising at least an acidic, basic, hydrophilic, hydrophobic or neutral peptide linked to an acidic peptide or nonpeptidic polyanion for use in targeting the aforementioned attached peptide to a bone fracture surface. In some embodiments, a conjugated peptide expresses an anabolic function that acts through PTH receptor 1, and various formats of targeting ligands guide the drug to raw hydroxyapatite. This system offsets some side effects caused by free anabolic drug, such as high blood calcium concentration | 2020-10-08 |
20200316175 | NUTRITIONAL COMPOSITION FOR TREATING OR PREVENTING IMPAIRED MOBILITY - A method of treating or preventing impaired mobility in an older adult includes administering to the older adult an effective amount of a composition containing at least one ingredient for cognitive ability, at least one ingredient for muscle and/or bone quality, and at least one ingredient for joint quality and/or functionality. The older adult can be an elderly individual and/or can have a condition that is one or more of frailty, pre-frailty, sarcopenia, recovering from sarcopenia, malnutrition, at risk of malnutrition, undergoing rehabilitation, and being scheduled to undergo rehabilitation, disorders impacting mobility such as osteoporosis, osteoarthritis, pre-osteoarthritis, osteopenia, cognitive decline. In a non-limiting example of the composition, the at least one ingredient for muscle and/or bone quality and the at least one ingredient for joint quality include a protein source, omega-3 fatty acids, and a polyphenol. | 2020-10-08 |
20200316176 | SCARRING REDUCING WOUND TREATMENT - Undue scarring of healing wounds is decreased and/or the relapse rate of wounds is lowered by applying a composition that includes hemoglobin to the wound area. At least 40% of the hemoglobin in the composition is provided in CO-charged form. | 2020-10-08 |
20200316177 | PHARMACEUTICAL COMPOSITION FOR PREVENTING OR TREATING INFLAMMATORY BOWEL DISEASE - The present invention relates to a pharmaceutical composition for preventing or treating inflammatory disease, which contains, as an active ingredient, a | 2020-10-08 |
20200316178 | FORMULATIONS COMPRISING GLUCOCEREBROSIDASE AND ISOFAGOMINE - The invention provides a composition of glucocerebrosidase, such as velaglucerase alfa, and isofagomine, in a molar ratio of at least about 1:2.5. Also provided is a use of the composition for treatment of a disorder related to a dysfunction in a GCase pathway. The disorder could be a lysosomal storage disease, such as Gaucher disease, Fabry disease, Pompe disease, a mucopolysaccharidoses, or multiple system atrophy. The disorder could also be a neurodegenerative disorder, such as Parkinson disease, Alzheimer's disease, or Lewy body dementia. The composition can have 0.5 to 5.0 mg/kg of glucocerebrosidase and isofagomine in at least about a 3-fold molar excess to the glucocerebrosidase. The composition can be administered intravenously or subcutaneously. | 2020-10-08 |
20200316179 | COMPOSITIONS AND METHODS FOR TREATMENT OF HOMOCYSTINURIA - Provided herein are improved compositions and methods for enzyme replacement therapy using modified human cystathionine beta synthase (CBS) in the treatment of homocystinuria and related diseases and disorders. | 2020-10-08 |
20200316180 | DNA VACCINES AND METHODS FOR THE PREVENTION OF TRANSPLANTATION REJECTION - Methods for preventing, delaying the onset of, or treating rejection of an allograft using a DNA vaccine, where the vaccine can comprise a polynucleotide encoding a pro-apoptotic protein, like BAX and/or a polynucleotide encoding an autoantigen or donor antigen, like secreted glutamic acid decarboxylase 55. Administering one of the DNA vaccines to a transplant recipient, as described herein, can induce a donor specific tolerogenic response. | 2020-10-08 |
20200316181 | Peptide Conjugated Particles - The present invention provides compositions comprising peptide-coupled biodegradable poly(lactide-co-glycolide) (PLG) particles. In particular, PLG particles are surface-functionalized to allow for coupling of peptide molecules to the surface of the particles (e.g., for use in eliciting induction of immunological tolerance). | 2020-10-08 |
20200316182 | NOVEL PEPTIDES AND COMBINATION OF PEPTIDES AS TARGETS OR ACTIVE INGREDIENTS FOR USE IN IMMUNOTHERAPY AGAINST AML AND OTHER CANCERS - The present invention relates to peptides, proteins, nucleic acids and cells for use in immunotherapeutic methods. In particular, the present invention relates to the immunotherapy of cancer. The present invention furthermore relates to tumor-associated T-cell peptide epitopes, alone or in combination with other tumor-associated peptides that can for example serve as active pharmaceutical ingredients of vaccine compositions that stimulate anti-tumor immune responses, or to stimulate T cells ex vivo and transfer into patients. Peptides bound to molecules of the major histocompatibility complex (MHC), or peptides as such, can also be targets of antibodies, soluble T-cell receptors, and other binding molecules. | 2020-10-08 |
20200316183 | NOVEL PEPTIDES AND COMBINATION OF PEPTIDES FOR USE IN IMMUNOTHERAPY AGAINST PANCREATIC CANCER AND OTHER CANCERS - The present invention relates to peptides, proteins, nucleic acids and cells for use in immunotherapeutic methods. In particular, the present invention relates to the immunotherapy of cancer. The present invention furthermore relates to tumor-associated T-cell peptide epitopes, alone or in combination with other tumor-associated peptides that can for example serve as active pharmaceutical ingredients of vaccine compositions that stimulate anti-tumor immune responses, or to stimulate T cells ex vivo and transfer into patients. Peptides bound to molecules of the major histocompatibility complex (MHC), or peptides as such, can also be targets of antibodies, soluble T-cell receptors, and other binding molecules. | 2020-10-08 |
20200316184 | BIOCONJUGATES OF E. COLI O-ANTIGEN POLYSACCHARIDES, METHODS OF PRODUCTION THEREOF, AND METHODS OF USE THEREOF - A bioconjugate of an | 2020-10-08 |
20200316185 | VACCINES AND METHODS OF VACCINATION AGAINST SCHISTOSOMA - A method of immunizing a human against infection by parasitic worms, comprising orally administering a live attenuated recombinant bacterium, expressing at least one antigen corresponding to a parasitic worm antigen; and a sterile injectable vaccine comprising the at least one antigen corresponding to a parasitic worm antigen. The method is effective against worms, including schistosomes. | 2020-10-08 |
20200316186 | MULTI-SUBUNIT VACCINES TO ELICIT BOTH MHC- AND CD1-RESTRICTED T CELL RESPONSES - Provided herein are subunit vaccine compositions comprising a nanocarrier and a lipid antigen, a peptide antigen or combinations thereof that elicit bother a CD1-restricted and an MHC-restricted T cell response in a subject. Methods for making and using the subunit vaccine compositions are also provided. | 2020-10-08 |
20200316187 | CHIMERIC YELLOW FEVER ZIKA VIRUS STRAIN - The present invention relates to chimeric yellow fever—Zika strains and attenuated versions thereof, wherein the nucleotide sequence encoding the signal sequence and prME protein of said yellow virus is replaced by a nucleotide sequence encoding the signal sequence and the prME protein of a Zika virus. | 2020-10-08 |